Future of Acute Severe Ulcerative Colitis
Author Information
Author(s): Pillay Leshni, Selvarajah Janakan, Andrew Bridgette, Christensen Britt, Macrae Finlay, Segal Jonathan P.
Primary Institution: Royal Melbourne Hospital
Hypothesis
We aim to present an up to date review and envisage future treatment of ASUC without steroids based on current trials and data.
Conclusion
Corticosteroids remain the mainstay therapy for ASUC despite reported adverse events with their use.
Supporting Evidence
- 30% of patients have steroid refractory ASUC.
- Colectomy rates for ASUC have remained steady despite advancements in therapies.
- Infliximab and cyclosporine are well-studied for salvage therapy.
Takeaway
This study looks at how to treat a serious bowel disease called acute severe ulcerative colitis without using steroids, which can have bad side effects.
Methodology
This is a narrative review summarizing current treatment options and future directions for managing acute severe ulcerative colitis.
Potential Biases
The review may be influenced by the authors' perspectives and the limited availability of high-quality data.
Limitations
The review lacks high-quality head-to-head randomized controlled trials to assess the effectiveness and safety of proposed therapies.
Participant Demographics
The review discusses a population with acute severe ulcerative colitis, but specific demographics are not detailed.
Statistical Information
P-Value
0.01
Confidence Interval
95% CI from 68–72%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website